Replies to post #485269 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Not at all!!!

It means that the ADL endpoint is only sensitive enough for mild to moderate stage Alzheimer’s disease and not for MCI and/or early stage Alzheimer’s disease.

The OLE study for blarcamesine will show statistical significance of blarcamesine as expected.

GOD bless,

[Steady_T]

Placebo and 30 mg subjects will likely get worse over time. Some of the 50 mg possible also.

What's your point?